[Graphic Omitted]                                                      EXHIBIT A




For Immediate Release

For Further Information Contact:
Yoram Ashery                                           Fern Lazar/David Carey
Given Imaging Ltd.                                     Lazar Partners Ltd.
                                                       Phone: (866) GIVEN IR
                                                       flazar@lazarpartners.com
                                                       dcarey@lazarparters.com


          GIVEN IMAGING LTD. FILES REGISTRATION STATEMENT FOR PROPOSED
                       PUBLIC OFFERING OF ORDINARY SHARES

YOQNEAM, Israel - May 24, 2004 - Given Imaging Ltd. (NASDAQ: GIVN) announced
today that it has filed a registration statement with the U.S. Securities and
Exchange Commission for a proposed public offering of its ordinary shares.

The Company expects to sell 1,500,000 ordinary shares and certain selling
shareholders expect to sell 1,005,000 ordinary shares. In addition, certain
selling shareholders will sell up to 375,750 additional shares if the
underwriters exercise their overallotment option. Merrill Lynch, Pierce, Fenner
& Smith Incorporated and Citigroup Global Markets Inc. are acting as joint
book-running managers for the offering, and CIBC World Markets and Wells Fargo
Securities are co-managers.

Given Imaging develops, manufactures and markets diagnostic products for
disorders of the gastrointestinal tract. The company has developed a proprietary
approach to visual examination of the gastrointestinal tract through the use of
miniaturized video camera contained in a disposable capsule. The capsule is
easily ingested by the patient and moves naturally through the gastrointestinal
tract without discomfort to the patient while wirelessly transmitting high
quality color images and data to a portable recorder.

The offering of the ordinary shares is made only by means of a prospectus which,
when available, may be obtained by writing or calling the prospectus departments
of either Merrill Lynch at 4 World Financial Center, New York, NY 10080, (212)
449-1000, or Citigroup Global Markets Inc., 140 58th Street, Brooklyn, NY 11220,
(718) 765-6732.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy ordinary shares
of Given Imaging, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state.

                                  ------------



This press release contains forward-looking statements about Given Imaging with
respect to its planned public offering within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
For example, statements in the future tense, words such as "anticipates,"
"estimates," "expects," "intends," "plans," "believes," and words and terms of
similar substance used in connection with any discussion of future operating or
financial performance identify such forward-looking statements. Those
forward-looking statements are not guarantees of future performance and actual
results could differ materially from our current expectations as a result of
numerous factors, including but not limited to the following: market perceptions
of our planned public offering, decisions made by the selling shareholders, and
factors affecting our business, such as changes in regulatory environment, our
success in implementing our sales, marketing and manufacturing plan, protection
and validity of patents and other intellectual property rights, the impact of
currency exchange rates, the effect of competition by other companies, the
outcome of future litigation, the reimbursement policies for our product from
healthcare payors, quarterly variations in operating results, the possibility of
armed conflict or civil or military unrest in Israel and other risks disclosed
in our filings with the U.S. Securities Exchange Commission.